1. Home
  2. RYTM vs CDP Comparison

RYTM vs CDP Comparison

Compare RYTM & CDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • CDP
  • Stock Information
  • Founded
  • RYTM 2008
  • CDP 1988
  • Country
  • RYTM United States
  • CDP United States
  • Employees
  • RYTM N/A
  • CDP N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • CDP Real Estate Investment Trusts
  • Sector
  • RYTM Health Care
  • CDP Real Estate
  • Exchange
  • RYTM Nasdaq
  • CDP Nasdaq
  • Market Cap
  • RYTM 3.1B
  • CDP 3.5B
  • IPO Year
  • RYTM 2017
  • CDP N/A
  • Fundamental
  • Price
  • RYTM $57.07
  • CDP $29.68
  • Analyst Decision
  • RYTM Strong Buy
  • CDP Buy
  • Analyst Count
  • RYTM 10
  • CDP 7
  • Target Price
  • RYTM $66.90
  • CDP $33.14
  • AVG Volume (30 Days)
  • RYTM 549.1K
  • CDP 682.9K
  • Earning Date
  • RYTM 02-20-2025
  • CDP 02-06-2025
  • Dividend Yield
  • RYTM N/A
  • CDP 3.95%
  • EPS Growth
  • RYTM N/A
  • CDP N/A
  • EPS
  • RYTM N/A
  • CDP 1.21
  • Revenue
  • RYTM $112,530,000.00
  • CDP $749,503,000.00
  • Revenue This Year
  • RYTM $63.77
  • CDP N/A
  • Revenue Next Year
  • RYTM $44.91
  • CDP $4.59
  • P/E Ratio
  • RYTM N/A
  • CDP $24.75
  • Revenue Growth
  • RYTM 81.55
  • CDP 10.11
  • 52 Week Low
  • RYTM $35.17
  • CDP $22.20
  • 52 Week High
  • RYTM $68.58
  • CDP $34.22
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 52.43
  • CDP 37.61
  • Support Level
  • RYTM $52.71
  • CDP $29.55
  • Resistance Level
  • RYTM $60.12
  • CDP $30.22
  • Average True Range (ATR)
  • RYTM 2.11
  • CDP 0.53
  • MACD
  • RYTM -0.00
  • CDP -0.01
  • Stochastic Oscillator
  • RYTM 58.93
  • CDP 34.91

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

About CDP COPT Defense Properties of Beneficial Interest

COPT Defense Properties is a real estate investment trust that acquires, manages, and leases office and data center properties throughout the U.S. The majority of the company's real estate portfolio is composed of office buildings in the Baltimore-Washington Corridor and Northern Virginia area. COPT derives nearly all of its income in the form of rental revenue from tenants. Most of the company's revenue comes from the leasing of properties to U.S. Government agencies and its contractors in the national security, defense, and IT sectors, such as Northrop Grumman and Boeing. Regional offices in urban submarkets make also make up a sizable percentage of COPT's total square footage.

Share on Social Networks: